1. Home
  2. CBRE vs KLTOW Comparison

CBRE vs KLTOW Comparison

Compare CBRE & KLTOW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CBRE
  • KLTOW
  • Stock Information
  • Founded
  • CBRE 1906
  • KLTOW N/A
  • Country
  • CBRE United States
  • KLTOW United States
  • Employees
  • CBRE N/A
  • KLTOW 3
  • Industry
  • CBRE Real Estate
  • KLTOW Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • CBRE Finance
  • KLTOW Health Care
  • Exchange
  • CBRE Nasdaq
  • KLTOW Nasdaq
  • Market Cap
  • CBRE 41.3B
  • KLTOW N/A
  • IPO Year
  • CBRE 2004
  • KLTOW 2022
  • Fundamental
  • Price
  • CBRE $140.65
  • KLTOW $0.25
  • Analyst Decision
  • CBRE Buy
  • KLTOW
  • Analyst Count
  • CBRE 9
  • KLTOW 0
  • Target Price
  • CBRE $152.78
  • KLTOW N/A
  • AVG Volume (30 Days)
  • CBRE 1.4M
  • KLTOW N/A
  • Earning Date
  • CBRE 07-29-2025
  • KLTOW N/A
  • Dividend Yield
  • CBRE N/A
  • KLTOW N/A
  • EPS Growth
  • CBRE 2.39
  • KLTOW N/A
  • EPS
  • CBRE 3.28
  • KLTOW N/A
  • Revenue
  • CBRE $36,742,000,000.00
  • KLTOW N/A
  • Revenue This Year
  • CBRE $14.60
  • KLTOW N/A
  • Revenue Next Year
  • CBRE $9.27
  • KLTOW N/A
  • P/E Ratio
  • CBRE $42.90
  • KLTOW N/A
  • Revenue Growth
  • CBRE 13.15
  • KLTOW N/A
  • 52 Week Low
  • CBRE $91.19
  • KLTOW N/A
  • 52 Week High
  • CBRE $147.75
  • KLTOW N/A
  • Technical
  • Relative Strength Index (RSI)
  • CBRE 59.93
  • KLTOW N/A
  • Support Level
  • CBRE $139.28
  • KLTOW N/A
  • Resistance Level
  • CBRE $142.46
  • KLTOW N/A
  • Average True Range (ATR)
  • CBRE 2.88
  • KLTOW 0.00
  • MACD
  • CBRE -0.22
  • KLTOW 0.00
  • Stochastic Oscillator
  • CBRE 66.23
  • KLTOW 0.00

About CBRE CBRE Group Inc

CBRE Group provides a wide range of real estate services to owners, occupants, and investors worldwide, including leasing, property and project management, and capital markets advisory. CBRE's investment management arm manages over $140 billion for clients across diverse public and private real estate strategies.

About KLTOW Klotho Neurosciences Inc. Warrant

Klotho Neurosciences Inc is in the development of essential medicines for the treatment of chronic diseases: Cancer, Cardiovascular, and Neurodegenerative disorders. The Company currently has acquired two licensed platforms: a generic drug portfolio and a biosimilar biologics platform that uses biologic therapies to treat cancer, and a proprietary, patented gene therapy platform which uses a gene therapy approach to introduce a therapeutic protein called Klotho inside the body to treat neurodegenerative diseases. Company pipeline includes KLTO 101, KLTO 202, KLTO 301.

Share on Social Networks: